Product Name: Fetal bovine serum
Product Code: BS-1101
Cultivate cells: BMDC
Figure 1. Cell culture in this study was conducted using Oposse fetal bovine serum
By utilizing the power of the innate immune system, nanovaccines can induce tumor specific immune responses, which is a promising strategy in cancer immunotherapy. However, traditional vaccine design requires the simultaneous loading of antigens and adjuvants, which is very complex and poses challenges for large-scale production. The team led by Professor Zhang Xuanbo from the Tenth Affiliated Hospital of Southern Medical University has developed a tumor nano vaccine platform, which integrates adjuvant function into delivery carriers using branched poly (guanidine) nano vaccines. These nanovaccines are produced by modifying polyethyleneimine (PEI) with various guanidine groups, converting the cytotoxicity of PEI into innate immune activation. The PolyGu nanovaccine based on Poly PBG effectively stimulates dendritic cells, promotes their maturation through TLR4 and NLRP3 pathways, and exhibits strong in vivo immune activity. They significantly inhibited tumor growth and prolonged the survival rate of mice. PolyGu also demonstrates the potential for building more effective mRNA based nanovaccines, providing a platform for personalized cancer vaccines. This work advances cancer immunotherapy towards potential clinical applications by introducing the paradigm of developing self adjuvant nanovaccines.
The study was published on February 26, 2024 in the international journal ACS Nano, titled Self Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
IF=17.1。
Figure 2. Research published in the international journal ACS Nano
Figure 3. Images in the article
https://pubs.acs.org/doi/10.1021/acsnano.3c11637
Scan to follow